Bumetanide: radioimmunoassay and pharmacokinetic profile in humans.
A simple, specific, and sensitive radioimmunoassay was developed for the determination of the diuretic bumetanide in plasma and urine. Antiserum to bumetanide was obtained from rabbits immunized with an immunogen prepared by covalently coupling the glycine conjugate of bumetanide to bovine serum albumin. Following extraction of the sample at pH 5.5 with ether, radioimmunoassay of the residue from the ether extract allows for the determination of bumetanide with a limit of sensitivity of about 1 ng/ml using 0.1 ml of plasma or urine. The specificity of the radioimmunoassay was established by comparison with specific radiometric and spectrofluorometric techniques. The pharmacokinetic profile of bumetanide in eight human subjects receiving single 2-mg oral doses of the drug was elucidated using the radioimmunoassay. The peak plasma levels ranged from 39 to 50 ng/ml at 1-4 hr after administration and declined with a mean apparent half-life of 1.17 hr. The mean plasma clearance rate was calculated to be 255 ml/min. During the first 24 hr, a mean of 43% of the bumetanide dose was excreted in the urine as intact drug.
D000328:Adult; D000818:Animals; D000917:Antibody Formation; D002034:Bumetanide / Q000032:analysis* / Q000276:immunology / Q000378:metabolism; D002417:Cattle; D004232:Diuretics / Q000032:analysis*; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008722:Methods; D008875:Middle Aged; D011817:Rabbits / Q000276:immunology; D011863:Radioimmunoassay; D012710:Serum Albumin, Bovine; D013050:Spectrometry, Fluorescence
D004232:Diuretics; D002034:Bumetanide; D012710:Serum Albumin, Bovine